Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $3.0 million.

  • Indivior Pharmaceuticals' Depreciation & Amortization (CF) fell 2500.0% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year increase of 10000.0%. This contributed to the annual value of $29.0 million for FY2024, which is 9333.33% up from last year.
  • Per Indivior Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $3.0 million for Q3 2025, which was down 2500.0% from $5.0 million recorded in Q1 2025.
  • Indivior Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $18.0 million during Q4 2024, with a 5-year trough of $2.0 million in Q4 2023.
  • In the last 4 years, Indivior Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $4.0 million in 2022 and averaged $5.1 million.
  • In the last 5 years, Indivior Pharmaceuticals' Depreciation & Amortization (CF) crashed by 6000.0% in 2023 and then skyrocketed by 80000.0% in 2024.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Depreciation & Amortization (CF) stood at $5.0 million in 2022, then tumbled by 60.0% to $2.0 million in 2023, then soared by 800.0% to $18.0 million in 2024, then plummeted by 83.33% to $3.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $3.0 million in Q3 2025, compared to $5.0 million in Q1 2025 and $18.0 million in Q4 2024.